Literature DB >> 12373448

Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons.

Nancy A Ator1.   

Abstract

RATIONALE: If a psychoactive drug shares discriminative effects with one that maintains self-administration, it is often inferred that the test drug is likely to be self-administered and to have abuse liability. This presumed predictive relationship has not been studied directly, however.
OBJECTIVE: To determine at the level of the individual subject (1) whether a novel drug dose that shares discriminative effects with a reinforcing drug dose also will serve as a reinforcer, and (2) whether the results of generalization tests for drugs pharmacologically similar to the training drug predict whether the test drugs will or will not be self-administered.
METHODS: Baboons were trained to discriminate midazolam (0.32 mg/kg, IV) from saline and also under a schedule of IV drug reinforcement. At the beginning of a period of self-administration, the first self-injection was followed 10 min later by a drug discrimination test session. The baboon then had the opportunity to self-administer the same dose 24 h/day (3-h timeout after each injection). A second drug discrimination test followed the last self-injection of the condition.
RESULTS: Zolpidem and imidazenil shared discriminative effects with midazolam. Zolpidem was reinforcing in all baboons, but imidazenil was not. Chlordiazepoxide partially shared discriminative effects with midazolam, and the rate of self-administration was low. Pentobarbital did not share discriminative effects with midazolam, but was reinforcing. For all drugs, some doses did not share discriminative effects with midazolam but were reinforcing. Generalization gradients from tests after the last self-injection were similar to those after the first self-injection.
CONCLUSIONS: The discriminative effect of a drug in relation to a training drug of the same pharmacological class is not isomorphic with its reinforcing effectiveness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373448     DOI: 10.1007/s00213-002-1076-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

Review 1.  Early preclinical studies of discriminable sedative and hallucinogenic drug effects.

Authors:  Herbert Barry; James B Appel
Journal:  Psychopharmacology (Berl)       Date:  2008-08-20       Impact factor: 4.530

2.  A within-subject assessment of the discriminative stimulus and reinforcing effects of self-administered cocaine in rhesus monkeys.

Authors:  Jennifer L Martelle; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

Review 3.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

4.  Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats.

Authors:  Kathryn L Schwienteck; Guanguan Li; Michael M Poe; James M Cook; Matthew L Banks; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2017-04-01       Impact factor: 4.530

Review 5.  Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.

Authors:  Amy Hauck Newman; Brandi L Blaylock; Michael A Nader; Jack Bergman; David R Sibley; Phil Skolnick
Journal:  Biochem Pharmacol       Date:  2012-07-03       Impact factor: 5.858

6.  Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens.

Authors:  Elif Engin; Konstantin I Bakhurin; Kiersten S Smith; Rochelle M Hines; Lauren M Reynolds; Wannan Tang; Rolf Sprengel; Stephen J Moss; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2014-02-19       Impact factor: 7.853

7.  Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.

Authors:  Nancy A Ator; John R Atack; Richard J Hargreaves; H Donald Burns; Gerard R Dawson
Journal:  J Pharmacol Exp Ther       Date:  2009-09-29       Impact factor: 4.030

8.  Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys.

Authors:  Marcus S Delatte; Carol A Paronis
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

9.  Reinforcing effects of compounds lacking intrinsic efficacy at α1 subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys.

Authors:  Nina M Shinday; Eileen K Sawyer; Bradford D Fischer; Donna M Platt; Stephanie C Licata; John R Atack; Gerard R Dawson; David S Reynolds; James K Rowlett
Journal:  Neuropsychopharmacology       Date:  2012-12-27       Impact factor: 7.853

10.  Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons.

Authors:  Amy K Goodwin; Barbara J Kaminski; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2012-09-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.